What is the appropriate management for a patient with acute decompensated heart failure with preserved ejection fraction who presents with cardiomegaly, central vascular congestion, and bibasilar infiltrates?

Management of Acute Decompensated HFpEF with Cardiomegaly, Central Vascular Congestion, and Bibasilar Infiltrates

Immediately initiate aggressive decongestion with intravenous loop diuretics, and simultaneously start guideline-directed medical therapy (GDMT) including SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRAs), and consider ARNIs or ARBs, as these disease-modifying therapies are safe and effective to initiate in the acute setting and will reduce both symptoms and mortality. 1

Immediate Acute Management: Decongestion First

Your patient presents with clear evidence of volume overload (cardiomegaly, central vascular congestion, bibasilar infiltrates). The priority is aggressive decongestion:

Loop Diuretics as Foundation

• Start high-dose intravenous loop diuretics immediately 1, 2
• This addresses the pulmonary congestion causing the bibasilar infiltrates and central vascular congestion
• Diuretics should be used judiciously but aggressively to reduce congestion and improve symptoms 1

Add Vasodilators if Blood Pressure Permits

• If systolic blood pressure is adequate (typically >90-100 mmHg), add intravenous vasodilators for rapid dyspnea relief 2
• This combination approach (diuretics + vasodilators) protects organs and avoids toxicities like hypotension and renal dysfunction 3

Escalation Strategies for Diuretic Resistance

If initial diuretic therapy proves inadequate:

• Dual nephron blockade: Add thiazide diuretics to loop diuretics 2
• Natriuretic doses of MRAs can enhance diuresis 2
• Ultrafiltration may be considered if diuretic strategies fail, though use cautiously if renal function worsens 4, 2

Critical Pitfall: Avoid Inotropes Unless Hypotensive

Do not use inotropic agents (dobutamine, milrinone, or levosimendan) unless the patient is hypotensive with evidence of poor tissue perfusion 3. Recent evidence shows levosimendan in elderly HFpEF patients may transiently improve hemodynamics but provides no long-term prognostic benefit and lacks cost-effectiveness 5. Inotropes increase mortality due to proarrhythmic effects and should be given in lowest doses for shortest duration if absolutely necessary 3.

Simultaneous Initiation of Disease-Modifying GDMT

The 2023 ACC guidelines explicitly state that GDMT initiation is safe and effective in both acute and chronic-care settings 1. Do not wait for discharge to start these therapies:

Core GDMT for HFpEF (Start in Hospital):

1. SGLT2 inhibitors (dapagliflozin or empagliflozin) - reduce symptoms, functional capacity, and mortality 1
2. Mineralocorticoid receptor antagonists (MRAs) - spironolactone or eplerenone 1
3. ARNIs (sacubitril/valsartan) or ARBs - for additional neurohormonal blockade 1

Rationale for Early Initiation:

Starting these medications during hospitalization improves adherence and outcomes. The evidence shows that early initiation of disease-modifying therapies after hemodynamic stability, particularly SGLT2 inhibitors and MRAs, improves outcomes in acute HFpEF 6. Waiting until discharge risks non-initiation and worse prognosis 7.

Comorbidity Management is Essential

HFpEF management requires aggressive treatment of contributing comorbidities 1:

• Hypertension control - critical given the central vascular congestion
• Diabetes management - consider GLP-1 receptor agonists which improve outcomes 6
• Atrial fibrillation - rate/rhythm control if present
• Coronary artery disease, CKD, obesity, obstructive sleep apnea - all require targeted therapy 1

Diagnostic Considerations Before Discharge

Given the cardiomegaly, ensure you're not missing HFpEF mimics that require specific therapies 1:

• Cardiac amyloidosis - look for increased LV wall thickness; consider monoclonal protein screen and technetium pyrophosphate scan
• Hypertrophic cardiomyopathy - unexplained LV hypertrophy
• High-output heart failure - check for anemia, AV malformations, cirrhosis, thiamine deficiency
• Pericardial disease - history of cardiac surgery, radiation, or pericarditis

If clinical suspicion exists, cardiac MRI can help differentiate these conditions 1.

Post-Discharge Strategy

Residual congestion before discharge is the strongest predictor of 30-day HF readmission 7. Before discharge:

• Ensure clinical euvolemia (no orthopnea, minimal peripheral edema, clear lung bases)
• Confirm patient is on all appropriate GDMT medications 1
• Arrange early follow-up within 7-14 days 7
• Optimize medication adherence strategies 7

Beta-Blocker Consideration

Beta-blockers are NOT routine GDMT for HFpEF unless specific indications exist 1:

• Prior myocardial infarction (within 3 years)
• Angina pectoris
• Atrial fibrillation requiring rate control

If used, monitor exercise tolerance due to risk of chronotropic incompetence 1.